The European Society of Gene & Cell Therapy (ESGCT) has become the epicenter of what’s next in biotech: where the most audacious ideas in cell and gene therapy come to play before they hit the clinic.
This year we were lucky enough to have it in beautiful Sevilla, with all the right ingredients (aside from the best tapas): viral engineering, RNA re-writing, in vivo CAR-T innovation, and even cellular rejuvenation pushing the boundaries of longevity.
If the last decade was about proving that genetic medicines can work, 2025 is about re-programming biology itself: moving from cutting and adding genes to editing, tuning, and rejuvenating them.
Here’s what stood out to us from four days of scientific overload:
1. From one-shot cures to programmable platforms
Across sessions, a clear theme emerged: the future isn’t just about fixing one gene at a time, but rather building modular, re-usable platforms that can write, silence, or boost expression in a controlled way.
Whether through engineered viral vectors, RNA-based systems, or synthetic circuits, researchers are finding ways to make therapies more flexible, reversible, and tissue-specific.
The next frontier of gene therapy looks much more like software: editable, easy to update, and adaptable to each patient.
2. RNA is the new playground
New approaches are turning RNA into a programmable material for therapy: from temporary gene editing and exon rewriting to synthetic RNA that can fine-tune protein levels.
Many of us dream on a soon reachable broader tissue reach, fewer safety issues, and scalable manufacturing.
RNA might just become the medicine itself, and not only the messenger.
3. Smarter, safer immune cells: CAR-T, CAR-NK, and the allogeneic arms race
The cell therapy field is evolving fast.
The spotlight has now shifted to engineering persistence, control, and affordability.
Off-the-shelf NK cells, dual-target CARs, and other hybrid designs all point toward more robust and accessible treatments.
The next generation of cell therapies must be designed not just for power, but for scalability and accessibility.
4. Aging, reprogrammed
Longevity science made a quiet but powerful entrance.
Partial cellular reprogramming and epigenetic rejuvenation are showing early evidence of restoring tissue function and slowing disease.
The concept is shifting from idea to therapy: helping cells stay young to prevent illness.
It’s early, but it could redefine what “advanced therapy” means in the next decade.
5. Viruses reinvented
Oncolytic and viral vectors are making a comeback. But this time as immune trainers, not just delivery tools. By combining viral delivery with immune activation, researchers are teaching the body to recognize and attack tumors.
This new wave of viral therapeutics blends the best of immuno-oncology and gene therapy: from “infectious” to “instructive”.
6. CNS: gene therapy for the brain is finally advancing
For a long time, treating the brain was one of the biggest challenges in medicine.
This year, new vectors, editing tools, and cell-based approaches showed that it may finally be possible to reach the brain effectively and safely.
The potential impact goes far beyond rare diseases, and it could open new options for pediatric, neurodegenerative and cognitive disorders that were once untreatable.
The big picture
Walking out of ESGCT 2025, one message stood out: we are moving from therapy to programmability.
- Biology is becoming editable at every level: DNA, RNA and even the epigenome.
- The line between curative and regenerative is fading.
- The next winners will be those who combine precision with flexibility, building tools that evolve with science itself.
Investor Takeaways
- Platform over product: Investors are looking beyond single-gene cures toward modular platforms that can address multiple diseases with one core technology.
- Delivery is still king, but precision is queen: AAV innovation continues, but the most exciting developments involve how precisely we can regulate and localize genetic activity. (at tissue and cellular level).
- RNA is the next investment wave: It’s versatile, re-dosable, and increasingly manufacturable at scale.
- CNS and aging are coming of age: Once considered uninvestable, both are now ripe for early bets as new delivery and reprogramming data accumulate.
- Integration will define winners: The future belongs to teams combining biology, computation, AI, and engineering: the ones who can treat cells as programmable systems.